Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockCJC-1295 No DAC / Hexarelin
Third-Party TestedPurity Standards
Total
$64.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Peptide blend
CJC-1295 (No DAC / Modified GRF 1-29)
Molecular formula
C152H252N44O42
Molecular weight
~3,368 g/mol
CAS number
863288-34-0
Sequence
Tetrasubstituted GRF(1-29), C-terminal amide (D-Ala at position 2)
Hexarelin
Molecular formula
C47H58N12O6
Molecular weight
887.04 g/mol
CAS number
140703-51-1
Sequence
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
Mechanism & Target Class
Mechanism & Target Class
Pairs two structurally distinct synthetic peptides. CJC-1295 (No DAC) / Modified GRF 1-29 is a 29-residue, C-terminally amidated analog corresponding to residues 1-29 of a 44-residue hypothalamic peptide, carrying four substitutions relative to the parent sequence (a D-alanine at position 2 plus changes at positions 8, 15, and 27) that confer resistance to enzymatic cleavage; its structural partner is a class B GPCR, characterized by cryo-EM. Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) whose structural partner is a class A GPCR; photoaffinity cross-linking has additionally identified the scavenger receptor CD36 as a binding partner in cardiac-membrane preparations. The two components are structurally unrelated and engage different binding partners; no single molecular target applies to the blend.
Storage & Handling
Storage & Handling
Lyophilized
20°C
typically stable 24-36 months desiccated and protected from light.
Avoid freeze-thaw; aliquot; protect from light and moisture.
References
References
Reviews
- 1
Ghigo E, et al. (1997). Eur J Endocrinol
- 2
Bowers CY. (1998). Cell Mol Life Sci
Clinical
- 3
Teichman SL, et al. (2006). J Clin Endocrinol Metab
- 4
Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab
- 5
Arvat E, et al. (2001). J Clin Endocrinol Metab
- 6
Bowers CY, et al. (1996). J Pediatr Endocrinol Metab
- 7
Bellone J, et al. (1995). J Clin Endocrinol Metab
- 8
Popovic V, et al. (1995). J Clin Endocrinol Metab
- 9
Arvat E, et al. (1994). J Clin Endocrinol Metab
- 10
Imbimbo BP, et al. (1994). Eur J Clin Pharmacol
- 11
Ghigo E, et al. (1994). J Clin Endocrinol Metab
- 12
Bowers CY, et al. (1990). J Clin Endocrinol Metab
Primary research
- 13
Structural study (cryo-EM) (2020). Nature Communications
- 14
Xu Z, et al. (2017). PubMed
- 15
Alba M, et al. (2006). Am J Physiol Endocrinol Metab
- 16
Jetté L, et al. (2005). Endocrinology
- 17
Bodart V, et al. (2002). Circulation Research
- 18
Giustina A, et al. (1997). Regul Pept
- 19
Bodart V, et al. (1999). Circ Res
- 20
Bresciani E, et al. (2004). Neuroendocrinology
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
